Newsletters

A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.

Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.

Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.

Capturing and assessing patient-reported outcomes is key to driving patient centricity in healthcare research and delivery. However, the life sciences industry has frequently struggled to gather adequate, high-quality participant data in clinical trials, resulting in costly delays for study teams.

In this post, we provide a comprehensive breakdown of the key challenges and opportunities associated with virtual clinical trials, examining the nuances of virtual components and how their implementation might affect each stage and touchpoint of the clinical trial journey.

Clinical trial sponsors are constantly seeking ways to collect better data, faster—accelerating clinical trials. Meanwhile, patients are increasingly likely to access healthcare services and interact with healthcare professionals digitally. Growing usage of telehealth also impacts patients’ expectations of clinical trials, with convenience and accessibility taking center stage.

Hybrid clinical trials drive efficiency, engagement, and effectiveness in clinical research. See whether a hybrid model could be a fit for your upcoming study.

ObvioHealth highlight the benefits of incorporating DCTs, as well as the challenges associated with DCTs, and call out specific use cases for DCTs.